Product Description
Gilead Sciences was developing gs-9901, an oral PI3K Inhibitor for adults with follicular lymphoma (FL), marginal zone lymphoma (MZL), chronic lymphocytic leukemia (CLL), or small lymphocytic lymphoma (SLL)
Mechanisms of Action: PI3K Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Gilead Sciences
Company Location: FOSTER CITY CA 94404
Company CEO: Daniel P. O’Day
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Chronic Lymphoid Leukemia|B-Cell Marginal Zone Lymphoma|Lymphocytic Chronic B-Cell Leukemia|Follicular Lymphoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
GS-US-325-1348 | P1 |
Terminated |
Lymphocytic Chronic B-Cell Leukemia|B-Cell Marginal Zone Lymphoma|Chronic Lymphoid Leukemia|Follicular Lymphoma |
2015-08-01 |